PMID- 29848950
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240327
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 10
IP  - 6
DP  - 2018 May 30
TI  - Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting.
LID - 10.3390/cancers10060168 [doi]
LID - 168
AB  - This special issue on mammalian target of rapamycin (mTOR) explores the 
      importance of mTOR in cell growth control and cancer. Cancer cells often exploit 
      mTOR as a mechanism to enhance their capacity to grow. While protein synthesis is 
      by far the best-characterized mTOR-driven process, this special issue also 
      describes a wider array of mTOR-driven biological processes that cancer cells 
      benefit from, including autophagy, cell cycle control, metabolic transformation, 
      angiogenic signaling, and anabolic processes such as nucleotide biosynthesis and 
      ribosomal biogenesis. Other areas of mTOR signaling covered in these reviews 
      delve into cell migration, inflammation, and regulation of transcription factors 
      linked to cancer progression.
FAU - Murray, James T
AU  - Murray JT
AUID- ORCID: 0000-0002-6928-2347
AD  - School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, 
      Trinity College Dublin, Dublin 2, Ireland. james.murray@tcd.ie.
FAU - Tee, Andrew R
AU  - Tee AR
AUID- ORCID: 0000-0002-5577-4631
AD  - Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 
      4XN, UK. teea@cardiff.ac.uk.
LA  - eng
PT  - Editorial
DEP - 20180530
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6025555
OTO - NOTNLM
OT  - cancer
OT  - mTOR
COIS- The authors declare no conflict of interest.
EDAT- 2018/06/01 06:00
MHDA- 2018/06/01 06:01
PMCR- 2018/05/30
CRDT- 2018/06/01 06:00
PHST- 2018/05/23 00:00 [received]
PHST- 2018/05/24 00:00 [accepted]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/01 06:01 [medline]
PHST- 2018/05/30 00:00 [pmc-release]
AID - cancers10060168 [pii]
AID - cancers-10-00168 [pii]
AID - 10.3390/cancers10060168 [doi]
PST - epublish
SO  - Cancers (Basel). 2018 May 30;10(6):168. doi: 10.3390/cancers10060168.